A Phase 1, Non-randomized, Open-label, Single-dose, Parallel Cohort Study To Compare The Pharmacokinetics Of Pf-05221304 In Adult Subjects With Varying Degrees Of Hepatic Impairment Relative To Subjects Without Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2018
At a glance
- Drugs PF 5221304 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 30 Jul 2018 Status changed from recruiting to completed.
- 12 Jul 2018 Planned End Date changed from 31 Jul 2018 to 19 Jul 2018.
- 12 Jul 2018 Planned primary completion date changed from 31 Jul 2018 to 19 Jul 2018.